On 11 January 2012, orphan designation (EU/3/11/945) was granted by the European Commission to Dr Ulrich Granzer, Germany, for ornithine phenylacetate for the treatment of acute liver failure.
The sponsorship was transferred to Voisin Consulting S.A.R.L., France, in September 2014, to Amiculum Consulting Limited, United Kingdom, in February 2017, and to Mallinckrodt Pharmaceuticals Ireland Limited, Ireland, in April 2018.
|Disease / condition||
Treatment of acute liver failure
|Date of decision||
|Orphan decision number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.